A Study on the Effect of High-Calorie Infant Formula on Growth and Nutrition in HIV-Infected Infants
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
In order to meet the optimal nutritional needs of HIV-infected infants, it is critical that nutritional intervention begin early. Early nutritional intervention may help reduce the susceptibility to or severity of primary HIV and/or opportunistic infections and add to the quality of life for children perinatally infected with HIV.
\[AS PER AMENDMENT 08/29/01: This study population will consist of infants from domestic sites and international sites.\] In this double-blind, controlled study perinatally HIV-exposed infants less than 15 days old \[AS PER AMENDMENT 08/29/01: "less than 15 days ...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Children may be eligible for this study if they:
- • Are 1 to 17 days old. (This study has been changed. Originally, infants 1 to 15 days old were eligible for this study.)
- • Weigh 4 or more pounds.
- • Were born to an HIV-positive mother.
- • Have a caregiver willing to measure and keep records of infant's food intake.
- • Exclusion Criteria
- Children will not be eligible for this study if they:
- • Are breast-fed.
- • Have certain disorders, including the inability to feed by mouth, or a life-threatening condition.
- • Take medication which affects growth.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Springfield, Massachusetts, United States
Seattle, Washington, United States
Bronx, New York, United States
La Jolla, California, United States
Long Beach, California, United States
Los Angeles, California, United States
Los Angeles, California, United States
Los Angeles, California, United States
Denver, Colorado, United States
New Haven, Connecticut, United States
Washington, District Of Columbia, United States
Miami, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Baltimore, Maryland, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Detroit, Michigan, United States
New Brunswick, New Jersey, United States
Newark, New Jersey, United States
Albany, New York, United States
Brooklyn, New York, United States
Great Neck, New York, United States
New York, New York, United States
New York, New York, United States
New York, New York, United States
New York, New York, United States
New York, New York, United States
Stony Brook, New York, United States
Syracuse, New York, United States
Durham, North Carolina, United States
Columbus, Ohio, United States
Charleston, South Carolina, United States
Dallas, Texas, United States
Houston, Texas, United States
Bayamon, , Puerto Rico
San Juan, , Puerto Rico
San Juan, , Puerto Rico
Newark, New Jersey, United States
St Louis, Missouri, United States
Tampa, Florida, United States
Augusta, Georgia, United States
New Orleans, Louisiana, United States
Jacksonville, Florida, United States
Durham, North Carolina, United States
Rochester, New York, United States
Miami, Florida, United States
Birmingham, Alabama, United States
Mobile, Alabama, United States
Farmington, Connecticut, United States
Fort Lauderdale, Florida, United States
Gainesville, Florida, United States
Riviera Beach, Florida, United States
Jackson, Mississippi, United States
Camden, New Jersey, United States
Richmond, Virginia, United States
Phoenix, Arizona, United States
Columbus, Georgia, United States
New Brunswick, New Jersey, United States
Orlando, Florida, United States
Pensacola, Florida, United States
Columbia, South Carolina, United States
San Antonio, Texas, United States
Nassau, , Bahamas
Belo Horizonte Mg, , Brazil
Rio De Janeiro Rj, , Brazil
Rio De Janeiro, , Brazil
Caguas, , Puerto Rico
Mayguez, , Puerto Rico
Ponce, , Puerto Rico
Patients applied
Trial Officials
Harland S Winter
Study Chair
James Oleske
Study Chair
Ross McKinney
Study Chair
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials